RANCHO CORDOVA, Calif., Dec. 5, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced Chris Xu, Ph.D., Chairman and Chief Executive Officer, will present a company overview at the LD Micro 12th Annual Main Event at the Luxe Sunset … Continued
ImmuneCyte to Begin Operations by Year End 2019 RANCHO CORDOVA, Calif., Nov. 26, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the company has closed on its joint venture agreement with HealthBanks Biotech (USA) Inc., a … Continued
Reports Second Consecutive Quarter of Positive Cash Flow; Recent Name Change Aligns with Shift in Strategic Focus Conference Call to be Held Today at 1:30 p.m. PST/4:30 p.m. EST RANCHO CORDOVA, Calif., November 19, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and … Continued
RANCHO CORDOVA, Calif., Nov. 14, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced it will delay its third quarter ended September 30, 2019 earnings release and subsequent earnings conference call, previously scheduled for … Continued
RANCHO CORDOVA, Calif., Nov. 12, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced it will delay its third quarter ended September 30, 2019 earnings release and conference call, previously scheduled for today, … Continued
Conference Call to be Held on November 12, 2019 RANCHO CORDOVA, Calif., Nov. 6, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing for regenerative medicine, today announced that the Company will release its financial results for the third quarter ended September 30, 2019 and provide a strategic corporate update on Tuesday, … Continued
ThermoGenesis to Focus on Developing Automated Cell Processing Tools and Services for the Cell and Gene Therapy Field RANCHO CORDOVA, Calif., Oct. 31, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing for regenerative medicine, today announced that the company will change its name to ThermoGenesis Holdings, Inc. (“ThermoGenesis”) in … Continued
RANCHO CORDOVA, Calif., Oct. 24, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Chris Xu, Ph.D., Chairman and Chief Executive Officer, will present a company overview at the Dawson James Securities 5th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida on Tuesday October 29, at 12:45 pm ET. Management will … Continued
ImmuneCyte to Begin Operations in Fourth Quarter of 2019 RANCHO CORDOVA, Calif., Oct. 21, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary, today announced that the company has entered into a definitive joint venture … Continued
RANCHO CORDOVA, Calif., October 14, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Jeff Cauble, Vice President of Finance and Principal Accounting Officer, will present at the 2019 BIO Investor Forum on Tuesday, October 22 at 4:00 pm PT. The … Continued